About Chronix Biomedical
Chronix Biomedical is a Healthcare company based in San Jose (United States) founded in 1997, and was acquired by OncoCyte in February 2021. Non-invasive diagnostics for cancer detection are developed through blood-based tests. Chronix Biomedical has raised $21.59 million across 9 funding rounds from investors including OncoCyte, Limitless Earth and Pentagram. The company has 2 employees. Its focus areas include Life Sciences, Clinical Genomics, Sequencing Based and Liquid Biopsy. Its legal entity is CHRONIX BIOMEDICAL INC. Its competitors include Guardant Health, GRAIL and Color; 3 of its 3 listed competitors have raised funding.
Company details
Chronix Biomedical was founded in 1997 in San Jose, United States, within the biomedical sector. Focus is placed on non-invasive diagnostics for cancer, including the Second Opinion blood test used alongside PSA screening to minimize false positives in prostate cancer cases. Development also includes a biomarker test for detecting minimal residual disease following chemotherapy treatments. Operations center on advancing these diagnostic tools for clinical use.
- Headquarters San Jose, United States
- Employees 2
- Stage Acquired
- SectorsHealthcare
- Website chronixbiomedical.com
- Social LinkedIn X Facebook
- Acquired by OncoCyte (Feb 2021)
- Legal Name Chronix Biomedical Inc
Funding Insights of Chronix Biomedical
Chronix Biomedical has successfully raised a total of $21.59M across 9 strategic funding rounds. The most recent funding activity was a Series E round of $100 thousand completed in September 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $21.59M
- Total Rounds 9
- Last Round Series E — $100,000
- First Round $2.27M
(Aug 2008)
- Investors Count 3
All 9 funding rounds of Chronix Biomedical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2019 | $100,000 | Series E | – | Limitless Earth | – |
| Jul 2017 | $3.31M | Series E | – | – | – |
| May 2017 | $1.47M | Series E | – | – | – |
| Oct 2016 | $5.01M | Series E | – | – | – |
| Apr 2014 | $3.43M | Series E | – | – | – |
| Oct 2012 | $1.42M | Series E | – | – | – |
| Mar 2011 | $2.78M | Series E | – | – | – |
| Sep 2010 | $1.8M | Series E | – | – | – |
| Aug 2008 | $2.27M | Series A | – | – |
4 investors in total: 4 institutional.
Investors in Chronix Biomedical
Chronix Biomedical has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include OncoCyte, Limitless Earth and Pentagram.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Technology companies are invested in by the private equity firm. | 2014 | limitlessearthplc.com | London, United Kingdom | |
Venture capital funding is provided to innovative technology startups. | pgvp.com | Sioux Falls, United States | ||
Brand design services are provided globally by Pentagram. | 1972 | pentagram.com | New York, United States | |
Non-invasive diagnostic test solutions for cancer treatment are developed. | 2009 | oncocyte.com | Irvine, United States |
Investor details for Chronix Biomedical
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Chronix Biomedical
28 people are tracked at Chronix Biomedical (14 in leadership, 4 in board & advisors, 10 in team); the tracked headcount is 2.
| Name | Role | Group |
|---|---|---|
Josh Riggs | President & CEO | Leadership |
Ekkehard Schütz | Chief Science Officer | Leadership |
Wen Li | Director, System Integration | Leadership |
Peter Hong | VP, General Counsel | Leadership |
Ryan Andrews | Vice President, Commercial | Leadership |
Brock Schweitzer | Senior Director, Pharma R&D | Leadership |
Shanet Oliver | CLIA Lab Operations Director | Leadership |
Eric Davis | Sr. Director, IT & Facilities | Leadership |
James Liu, CPA | Vice President Of Accounting, Controller, Treasurer, & Principal Accounting Officer | Leadership |
Julie Hufham | Associate Director, Marketing | Leadership |
Julia Beck | Director, Research Development | Leadership |
Mary Grace Sullivan | Director, CLIA Lab Services, Clinical Lab Scientist III | Leadership |
Mike Krnjaich | Regional Director | Leadership |
Dan Bailey | Associate Director, Product Management - Oncology | Leadership |
Andrew J. Last | Director | Board & advisors |
Alfred D. Kingsley | Director | Board & advisors |
Andy Arno | Chairman | Board & advisors |
Louis E. Silverman | Director | Board & advisors |
Yuh-Min Chiang | SVP, R&D & Product Development | Team |
Yaning Li | Senior Scientist, Mt(ascp) | Team |
8 more people are available in the full profile.
Complete people profiles for Chronix Biomedical
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Chronix Biomedical
4 dated milestones of Chronix Biomedical across 24 years, from founding to its latest funding, stage changes and deals.
- Founded Chronix Biomedical is founded.
- Funding First funding round of $2.3M.
- Funding Latest funding round, Series E, of $100K.
- Exit Acquired by OncoCyte.
Competitors of Chronix Biomedical
Chronix Biomedical has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, GRAIL and Color.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| grail.com | 2016 | Menlo Park, United States | $2B | 491 | Circulating tumor DNA is screened for early cancer detection. | |
| color.com | 2013 | Burlingame, United States | $491.44M | 687 | Cancer care is delivered through a virtual clinic by Color. |
Detailed competitors of Chronix Biomedical
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Chronix Biomedical
Websites that share an audience with Chronix Biomedical (chronixbiomedical.com).
Websites whose visitors overlap most with Chronix Biomedical. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
proteus.fr | proteus.fr | 100% | – | ||
biopartners.ch | biopartners.ch | 100% | – | ||
pepscan.nl | pepscan.nl | 100% | – | ||
| ptcbio.com | 100% | 24.4K | #1,154,739 | View details | |
| sigris.com | 100% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 20 similar websites and full traffic analytics for Chronix Biomedical
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 20 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Chronix Biomedical (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Chronix Biomedical
Complete news archive for Chronix Biomedical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Chronix Biomedical
Chronix Biomedical was founded in 1997 and raised its 1st funding round 11 years after it was founded.
Chronix Biomedical is headquartered in San Jose, United States. It is registered at San Jose, California, United States.
Chronix Biomedical is a funded company, having raised a total of $21.59M across 9 funding rounds to date. The company's 1st funding round was a Series A of $2.27M, raised on Aug 2008.
Chronix Biomedical has 2 employees.
Chronix Biomedical was founded in 1997 in San Jose, United States, within the biomedical sector. Focus is placed on non-invasive diagnostics for cancer, including the Second Opinion blood test used alongside PSA screening to minimize false positives in prostate cancer cases. Development also includes a biomarker test for detecting minimal residual disease following chemotherapy treatments. Operations center on advancing these diagnostic tools for clinical use.
Chronix Biomedical's top competitors include Guardant Health, GRAIL and Color.
Chronix Biomedical has 4 investors. Key investors include OncoCyte, Limitless Earth, Pentagram, and PrairieGold Venture Partners.
Chronix Biomedical operates through Chronix Biomedical Inc.
Yes. Chronix Biomedical was acquired by OncoCyte in February 2021.